The US Senate Finance Committee’s drug pricing legislation will likely only impact biopharma industry sales by about 2% and on balance, would represent a “positive” outcome for industry given the current state of the drug pricing debate, Bernstein analyst Ronny Gal concludes in a 26 November report.
The report focuses on three drug pricing reform initiatives most likely advance – the Finance bill, the Trump Administration’s International Pricing Index regulation, and the House drug